Actively Recruiting
StrataCTX® as a Steroid Sparing Device
Led by Columbia University · Updated on 2025-10-02
70
Participants Needed
1
Research Sites
264 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
CONDITIONS
Official Title
StrataCTX® as a Steroid Sparing Device
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years
- Ability to sign informed consent document
- Diagnosis of cutaneous T-cell lymphoma (CTCL) with contact dermatitis from topical mechlorethamine gel
- Diagnosis of CTCL with intractable pruritus
- Diagnosis of CTCL requiring frequent use of topical steroids for symptom relief
- Currently on chemotherapy or immunotherapy with drug-induced rash
You will not qualify if you...
- Currently undergoing radiotherapy
- Currently receiving oral steroids
- Unable to apply topical medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
Research Team
L
Larisa Geskin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here